List view / Grid view
Single-temperature incubation has been discussed for a long time in the pharmaceutical industry but only a few sites have implemented this system. Here, Guillaume Pinon, Head of the Microbiology Lab at Servier, discusses the use of single-temperature incubation in an aseptic production facility, outlining the regulatory considerations, strategic approach, challenges…
This in-depth focus features articles on single temperature incubation, endotoxin standards and aseptic connections in pharmaceutical manufacturing.
European Pharmaceutical Review Issue 3 includes articles on microbiology, downstream bioprocessing and drug development. Register your details now to download this exclusive content.
Here, EPR's Caroline Peachey explores some key considerations, approaches and strategies for pharmaceutical companies looking to outsource regulatory activities.
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
27 April 2016 | By Victoria White, Digital Content Producer
The decision from the EC was based on data from the international, double-blind, placebo-controlled Phase III RECOURSE study...
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
12 August 2013 | By Amgen
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement...
9 July 2013 | By Amgen
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe...
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
